Bi Asset Management Fondsmaeglerselskab A Halozyme Therapeutics, Inc. Transaction History
Bi Asset Management Fondsmaeglerselskab A
- $9.48 Billion
- Q4 2024
A detailed history of Bi Asset Management Fondsmaeglerselskab A transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Bi Asset Management Fondsmaeglerselskab A holds 427,207 shares of HALO stock, worth $26.3 Million. This represents 0.22% of its overall portfolio holdings.
Number of Shares
427,207
Previous 294,412
45.11%
Holding current value
$26.3 Million
Previous $16.9 Million
21.2%
% of portfolio
0.22%
Previous 0.29%
Shares
7 transactions
Others Institutions Holding HALO
# of Institutions
550Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.08 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$816 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$441 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$256 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$212 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.56B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...